Group 1 - The National Health Commission is promoting the experience of the Sanming medical reform to enhance the development of traditional Chinese medicine (TCM) and its innovation [1] - A series of policies have been introduced to accelerate the high-quality development of county-level TCM hospitals, with over 40% of these hospitals leading the establishment of county medical communities [1] - There are currently 3,099 tightly-knit county medical communities established across 2,199 counties and cities in China [1] Group 2 - The State Council has issued opinions to improve the quality of traditional Chinese medicine and promote the high-quality development of the TCM industry, emphasizing the use of evidence-based medicine to translate clinical experience into clinical evidence [1] - Research institutions suggest that strengthening the collaboration within the TCM industry chain and optimizing the industrial structure may accelerate the pace of mergers and acquisitions among leading companies [1] - The accelerated review of new TCM drugs, while ensuring quality and clinical efficacy, is expected to facilitate the rapid market entry of more high-quality innovative TCM products [1] Group 3 - Longshen Rongfa focuses on the research and development of pharmaceutical products, medical products, and health products, including traditional Chinese medicine and health food [2] - China Resources Sanjiu's product range covers various therapeutic areas, including cardiovascular, anti-tumor, digestive, orthopedic, pediatric, and anti-infection treatments, with notable products like Xuesaitong and Sanqi series [2]

Group 1 - The company, Longshen Rongfa (300534), is focusing on its main business while also paying close attention to the application and development trends of AI and other cutting-edge technologies in the pharmaceutical industry [1] - The company is actively exploring the integration of relevant technologies with its business operations [1]

证券日报网讯 1月20日，陇神戎发在互动平台回答投资者提问时表示，上市公司股价受国家宏观经济政 策、经济走势以及资本市场投资情绪、关注热点等诸多因素影响，公司经营稳健，市值管理是公司长期 重点工作，公司将继续按照既定战略目标，以高质量发展为主线，聚焦核心主业，持续抓好经营发展， 提升公司盈利能力，不断加强企业品牌建设和高质量信息披露工作，增强投资者回报水平，推动公司内 在价值的合理反映。 （编辑 袁冠琳） ...

Group 1 - The company focuses on the research, production, and sales of traditional Chinese medicine [1] - Currently, there are no business activities related to brain-machine interfaces [1]

Group 1 - The company, Longshen Rongfa (300534.SZ), focuses on the research, production, and sales of traditional Chinese medicine [1] - Currently, the company has no business related to brain-machine interfaces [1]

Core Viewpoint - The company will continue to focus on its main business and leverage the advantages of state-owned capital to strengthen its market presence and expand into OTC and untapped areas [1] Group 1: Business Strategy - The company is concentrating on two exclusive core products: Yuanhu Zhitong Pill and Xuanfei Zhiso Mixture, aiming to consolidate its existing market [1] - The company plans to actively expand into the generic drug market, health products line, and medical devices to cultivate new growth points [1] Group 2: Research and Development - The company is committed to increasing R&D investment and enhancing its R&D capabilities, aiming to build a collaborative innovation system and a long-term mechanism for R&D investment [1] - The company will continue to promote the secondary development of its main products while increasing R&D efforts in new drugs, classic formulas, and health-related fields to enrich its product pipeline and enhance core competitiveness [1]

Core Viewpoint - Gansu Longshen Rongfa Pharmaceutical Co., Ltd. has received official certification for its health product "Huangqi Danggui Capsules" from the Macao Special Administrative Region, allowing it to enter the Macao market without prior drug import permits, marking a significant milestone in the company's expansion into the Guangdong-Hong Kong-Macao Greater Bay Area and international markets [1][2]. Group 1 - The "Huangqi Danggui Capsules" are made from traditional medicinal materials Huangqi and Danggui, combined with microcrystalline cellulose and silicon dioxide, adhering to traditional Chinese medicine principles and modern formulation techniques, and have been scientifically validated for their protective functions against radiation hazards [1]. - The "Macao Non-Drug Certification" system is a unique regulatory framework established by the Macao government for high-value functional foods and health products, providing a clear pathway for quality health products and facilitating access to markets in Portuguese-speaking countries, the EU, Latin America, and the Middle East [2]. - The recognition of "Huangqi Danggui Capsules" not only serves as an authoritative endorsement of its quality, safety, and efficacy by the Macao government but also signifies a critical step in the company's strategy to internationalize traditional Chinese medicine health products [2]. Group 2 - In recent years, the company has actively expanded its international presence through its wholly-owned subsidiary, Gansu New Silk Road Industrial Investment Co., Ltd., targeting markets in East Asia, Central Asia, Southeast Asia, and Europe, with successful product registration and export sales in Russia, Kyrgyzstan, Singapore, and Thailand [2]. - The company plans to leverage its full industry chain advantages in traditional Chinese medicine cultivation, deep processing, research, and production to enhance product quality and technological innovation, while actively researching and aligning with health product regulations in different countries and regions [3]. - The company aims to provide high-quality health solutions derived from China to global consumers, contributing to the "Healthy China" initiative and the internationalization of traditional Chinese medicine [3].

Group 1 - The company announced the approval of the proposal to reappoint the accounting firm for the fiscal year 2025 during the sixth extraordinary general meeting of shareholders [2]

证券代码：300534 证券简称：陇神戎发 公告编号：2025-083 甘肃陇神戎发药业股份有限公司 2025年第六次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会未出现否决议案的情形； 2.本次股东会不涉及变更以往股东会已通过的决议的情形。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间： （1）现场会议召开时间：2025 年 12 月 19 日下午 14:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025年12月19日9:15—9:25，9:30—11:30和13:00—15:00；通过深圳证券交易 所互联网投票系统进行网络投票的时间为2025年12月19日9:15—15:00期间的任 意时间。 2.现场会议地点：甘肃省兰州市榆中县定远镇国防路 10 号公司六楼会议室 3.会议召开方式：本次股东会采取现场投票与网络投票相结合的方式召开 4.会议召集人：公司董事会 5.会议主持人：董事长康永红先生 6.本次股东会的召集、召开以及表决程序符合《公司法》等法律、行政法规 ...

北京德恒（兰州）律师事务所 关于甘肃陇神戎发药业股份有限公司 2025 年第六次临时股东会 之 法律意见书 甘肃省兰州市城关区雁园路 601 号甘肃省商会大厦 A 座 15 层 邮编：730030 2025 年第六次临时股东会之 法律意见书 致：甘肃陇神戎发药业股份有限公司 北京德恒（兰州）律师事务所（以下简称"本所"）受甘肃陇神戎发药业股 份有限公司（以下简称"陇神戎发""贵公司""公司"）委托，指派张军、杨 晓楠律师（以下简称"本所律师"）出席贵公司 2025 年第六次临时股东会（以 下简称"本次股东会"），并对本次股东会的合法性出具法律意见书。 本所律师列席了贵公司本次股东会，并根据本法律意见书出具日前已发生或 存在的事实和《中华人民共和国公司法》（以下简称《公司法》）、《中华人民 共和国证券法》（以下简称《证券法》）、《上市公司股东会规则》以及《甘肃 陇神戎发药业股份有限公司章程》（以下简称《公司章程》）等有关法律、法规 和规范性文件的有关规定出具本法律意见书。 为出具本法律意见书，本所律师审查了本次股东会的有关文件和材料。本所 律师已得到贵公司保证，其已提供了本所律师认为出具法律意见书所必需的材料， ...